Brief: Clover And Ascentage Pharma Announce Clinical Collaboration
09/12/2021 13:09
Dec 9 (Reuters) - Clover Biopharmaceuticals Ltd 2197.HK :
* CLOVER AND ASCENTAGE PHARMA ANNOUNCE CLINICAL
COLLABORATION TO
EVALUATE RECOMBINANT HUMAN TRAIL-TRIMER FUSION PROTEIN, SCB-313,
IN COMBINATION WITH IAP ANTAGONIST, APG-1387 FOR THE TREATMENT
OF PERITONEAL CARCINOMATOSIS
* ASCENTAGE PHARMA GROUP - WILL JOINTLY CONDUCT PHASE 1B/2
STUDY
TO EVALUATE SAFETY, TOLERABILITY, PK/PD, EFFICACY OF SCB-313
WITH APG-1387 WITH CLOVER
Source text for Eikon: ID:nGNX3S1lJW
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune